The license, which is co-owned by University of Maryland, Baltimore and Flagstaff-based Northern Arizona University, is for technology that forms the basis for a multivalent vaccine. Through the collaboration, Serenta Biotechnology will use its novel discovery platform to identify antigens produced in S. aureus infections. S. aureus bacteria are often antibiotic-resistant.
Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!
In addition, Serenta Biotechnology hopes to use its antigen discovery platform in collaboration with University of Maryland, Baltimore to develop vaccines for other deadly pathogens, such as Streptococcus pyogenes, Klebsiella pneumoniae and Acinetobacter baumannii.
More articles on healthcare quality:
Health officials investigate whooping cough outbreak in Baldwinsville (NY) School District
Hawaii health officials increase mumps tally to 65
Scientists create test to identify dormant HIV
